Cross-Sectional Study for an Ocular Imaging-Based Predictive Model of Inflammatory Skin Diseases Grounded in Traditional Chinese Medicine

Inclusion criteria

For patients with inflammatory skin disease:

Clinical diagnosis of one of the three target inflammatory skin diseases (psoriasis, atopic dermatitis, or urticaria).

Age ≥ 18 and ≤ 65 years, any sex.

Understands and signs informed consent.

For healthy controls:

Do not meet diagnostic criteria for any of the three inflammatory skin diseases above.

Age ≥ 18 and ≤ 65 years, any sex.

Understands and signs informed consent.

Exclusion criteria

For patients with inflammatory skin disease:

Exclude any subject meeting any of the following:

Refusal to undergo examinations.

Presence of acute/active infectious ocular disease (e.g., viral keratoconjunctivitis).

Corneal perforation or high-risk perforation where contact procedures cause severe photophobia, eye pain, inability to keep eyes open or fixate.

Nystagmus or other conditions that prevent fixation.

Pupillary non-dilation (e.g., posterior synechiae) that precludes fundus imaging.

Severe eyelid lesions (e.g., marked swelling, ectropion, entropion) that prevent globe exposure.

Participation in other clinical trials within the previous 3 months or concurrent participation in other interventional studies.

• Healthy control - exclusion criteria

Exclude any subject meeting any of the following:

Presence of other skin diseases that could affect study assessments (e.g., atopic dermatitis, urticaria, scabies).

Refusal to undergo examinations.

Acute/active infectious ocular disease (e.g., viral keratoconjunctivitis).

Corneal perforation or high-risk perforation that causes severe photophobia, eye pain, inability to keep eyes open or fixate during contact procedures.

Nystagmus or other reasons preventing fixation.

Pupillary non-dilation (e.g., posterior synechiae) that prevents fundus imaging.

Participation in other clinical studies within the previous 3 months or currently participating in other clinical trials.